サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757552

内皮機能障害の世界市場

Endothelial Dysfunction

出版日
ページ情報
英文 370 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
内皮機能障害の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 370 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

内皮機能障害の世界市場は2030年までに26億米ドルに到達

2024年に21億米ドルと推定される内皮機能障害の世界市場は、2024～2030年の分析期間においてCAGR 3.3％で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである侵襲的検査は、CAGR 4.1％を記録し、分析期間終了までに16億米ドルに達すると予測されます。非侵襲的検査分野の成長率は、分析期間のCAGRで2.0％と推定されます。

米国市場は5億7,400万米ドルと推定、中国はCAGR6.3％で成長予測

米国の内皮機能障害市場は、2024年に5億7,400万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.3%として、2030年までに5億930万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.5%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の内皮機能障害市場- 主要動向と促進要因のまとめ

内皮機能障害は全身疾患進行の中心的指標としてどのように台頭しているか？

内皮機能障害は、特に心血管障害、メタボリックシンドローム、慢性腎臓病など、いくつかの慢性疾患の病態生理における極めて重要なマーカーであり、その一因であるとの認識が高まっています。血管内皮（血管内を覆う単細胞層）は、血管拡張、血小板活性、白血球接着、平滑筋増殖を制御することにより、血管の恒常性を維持する上で重要な役割を果たしています。内皮細胞がその機能を失うと、一酸化窒素のような血管拡張因子とエンドセリン-1のような血管収縮因子のバランスが崩れ、炎症性・血栓性事象のカスケードが引き起こされます。これらの変化は、アテローム形成、動脈硬化、および血管リモデリングに好都合な環境を作り出し、内皮機能障害を高血圧、冠動脈疾患、および脳卒中の前駆症状および悪化因子にしています。

最近の臨床的動向は、顕在的な症状が現れる前であっても、疾患発症の初期段階における内皮機能障害の役割に光を当てつつあります。非対称ジメチルアルギニン（ADMA），循環内皮細胞，可溶性接着分子などのバイオマーカーが，血管傷害の早期指標として研究されています。上腕動脈のFMD（Flow-mediated dilation）は、現在も研究現場で最も一般的に使用されている非侵襲的評価ツールであるが、末梢動脈圧測定（PAT）やレーザードップラー血流計のような新しい測定法も臨床応用で普及しつつあります。重要なことは、内皮機能障害は心血管系の病態だけに限定されるものではなく、インスリン抵抗性、狼瘡のような自己免疫疾患、さらには血管性痴呆やアルツハイマー病のような神経血管疾患にも関与することが多くなってきていることで、その関連性は複数の医療領域にわたって広がってきています。

内皮障害が最も影響する疾患とその理由

内皮機能障害の最も重要な臨床的関連は、心臓代謝疾患において観察されます。2型糖尿病では、慢性的な高血糖により酸化ストレスが誘導され、一酸化窒素の生物学的利用能が損なわれ、内皮の老化が促進されます。この内皮傷害は糖尿病性腎症や網膜症のような微小血管合併症を悪化させ、同時に冠動脈疾患や末梢動脈疾患のような大血管の問題にも関与します。高血圧症では、血管壁への機械的ストレスの増大が内皮の活性化と炎症を引き起こし、血管のリモデリングと動脈硬化の上昇を促進します。このようなフィードバックループにより内皮は疾患進行の標的であると同時に媒介因子となり、診断および治療の重要な焦点としての役割が強化されます。

さらに、内皮機能障害は慢性腎臓病（CKD）において、特に腎灌流および糸球体濾過率の低下を促進するという顕著な役割を担っています。末期腎疾患患者では、全身性の内皮障害が心血管系リスクの上昇と相関しており、このコホートにおける死亡の主な原因となっています。全身性エリテマトーデスや関節リウマチなどの自己免疫疾患では、循環する炎症性サイトカインが内皮細胞接合部を障害し、血管透過性を増加させる。このような血管傷害の素因は、若い患者であっても心血管系のリスクを上昇させる。肺動脈性肺高血圧症（PAH）と勃起不全もまた、内皮を強く構成しており、血管機能障害が全身に及ぼす影響をさらに強調しています。これらの関連は，多臓器疾患の管理において内皮の健康が重要であることを示しています。

この領域における診断・治療戦略はどのように進化しているのか？

内皮機能評価における技術的進歩は、疾患検出と進行モニタリングに対するより積極的なアプローチを促進しつつあります。FMDのような従来の方法は、正確ではあるが、オペレーターの熟練と特殊な環境条件を必要とするため、拡張性に限界があります。これに対し、PAT、オシロメトリー、バイオインピーダンスを用いた新たな装置が、微小血管の反応性を評価するための、より利用しやすく自動化された代替手段を提供しています。ウェアラブルバイオセンサーやデジタルヘルスプラットフォームも血管の健康パラメータを継続的にモニターするために開発されており，リスクのある集団における内皮反応性の遠隔追跡の可能性を提供しています。同時に，分子診断学は，不顕性の段階で内皮障害を検出できるバイオマーカー・パネルによって，この情勢に磨きをかけています。

治療面では，いくつかの薬理学的介入が内皮保護を主目的として再利用あるいはデザインされつつあります。スタチン，ACE阻害薬，アンジオテンシン受容体拮抗薬（ARB）は，脂質低下作用や降圧作用とは別に内皮安定化作用を示します。ナトリウム-グルコース共輸送体-2（SGLT2）阻害薬やグルカゴン様ペプチド-1（GLP-1）受容体作動薬などの新しい薬剤クラス別は，糖尿病患者において血管保護作用を示し，その一部は内皮機能の改善に起因しています。抗炎症剤，一酸化窒素供与剤，抗酸化剤もまた，特に酸化ストレスが顕著な病因となる疾患において，臨床試験で検討されています。さらに、内皮前駆細胞（EPC）を含む再生戦略や、内皮一酸化窒素合成酵素（eNOS）制御を標的とした遺伝子編集ツールも、初期段階の開発段階にあります。これらの技術革新は、特に内皮の均衡を回復することを目的とした標的介入への道を開きつつあります。

内皮機能障害市場の需要増加の要因は？

世界の内皮機能障害市場の成長は、臨床、技術、規制の各エコシステムに収束しつつあるいくつかの要因によって牽引されています。その最たるものが、心血管疾患、糖尿病、腎臓病などの非感染性疾患による世界の負担の増加です。早期診断と個別化医療がますます重視されるようになったことで、医学界は予測ツールとして内皮バイオマーカーと血管画像診断技術に一層力を入れるようになっています。この需要は、臨床医と患者の双方、特に高リスクだが無症状の患者における潜在性血管障害に対する意識の高まりによってさらに高まっています。

その他の特典としては、製薬大手とバイオテクノロジー新興企業の双方による内皮を標的とした治療薬への研究開発投資の拡大があります。既存の心血管治療薬を内皮の修復のために再配置する動向と、心代謝と内皮の二重の効果を持つ新規薬剤の並行開発により、治療パイプラインの幅が広がっています。医療システムも、特に高度心臓病センターや代謝クリニックにおいて、内皮評価を日常的なリスク層別化モデルに組み込み始めています。デジタルヘルスの統合も重要な役割を果たしており、AIを活用した血管解析やモバイル診断プラットフォームがポイントオブケア検査や長期追跡を容易にしています。

最後に、規制機関は、PAHや全身性硬化症などの希少な内皮関連疾患に対処する治療薬に対する促進パスウェイや希少疾病指定を通じて、この分野におけるイノベーションをますます支援しています。心血管系のリスク管理とライフスタイルの改善を促進する公衆衛生キャンペーンは、内皮の健康を中心とした予防戦略を可能にする環境を作り出しています。診断的関連性、治療的意味合い、技術的応用可能性の拡大により、市場情勢は慢性疾患管理のより広範な展望に影響を及ぼしながら、大幅な成長を遂げようとしています。

セグメント

検査タイプ（侵襲的検査、非侵襲的検査）;原因（高血圧、糖尿病、肥満、高コレステロール血症、ベーチェット病）;エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、専門クリニックエンドユーザー）

調査対象企業の例（計34社）

  • Abbott Laboratories
  • Alam Medical SaRL
  • Alvimedica
  • Amgen Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Endothelix Inc.
  • Everist Health Inc.
  • Glucox Biotech AB
  • Johnson & Johnson
  • Lawrence Berkeley National Laboratory
  • Medizinische Messtechnik GmbH
  • Novartis AG
  • OrbusNeich Medical Group
  • Perimed AB
  • Pfizer Inc.
  • Sanofi S.A.
  • SMART Medical Ltd
  • SphingoTec GmbH
  • Stealth Peptides Inc.
  • ZOLL Medical Corporation

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36837

Global Endothelial Dysfunction Market to Reach US$2.6 Billion by 2030

The global market for Endothelial Dysfunction estimated at US$2.1 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Invasive Tests, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Noninvasive Tests segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$574.0 Million While China is Forecast to Grow at 6.3% CAGR

The Endothelial Dysfunction market in the U.S. is estimated at US$574.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$509.3 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Endothelial Dysfunction Market - Key Trends & Drivers Summarized

How Is Endothelial Dysfunction Emerging as a Central Indicator in Systemic Disease Progression?

Endothelial dysfunction is increasingly recognized as a pivotal marker and contributor to the pathophysiology of several chronic diseases, particularly cardiovascular disorders, metabolic syndrome, and chronic kidney disease. The endothelium-a single-cell layer lining the interior of blood vessels-plays a crucial role in maintaining vascular homeostasis by regulating vasodilation, platelet activity, leukocyte adhesion, and smooth muscle proliferation. When endothelial cells lose their functional integrity, the balance between vasodilators like nitric oxide and vasoconstrictors such as endothelin-1 is disrupted, triggering a cascade of inflammatory and pro-thrombotic events. These changes create a favorable environment for atherogenesis, arterial stiffness, and vascular remodeling, making endothelial dysfunction a precursor and aggravator of hypertension, coronary artery disease, and stroke.

Recent clinical investigations are shedding light on the role of endothelial dysfunction in the early phases of disease development, even before overt symptoms arise. Biomarkers such as asymmetric dimethylarginine (ADMA), circulating endothelial cells, and soluble adhesion molecules are now being studied as early indicators for vascular injury. Flow-mediated dilation (FMD) of the brachial artery remains the most commonly used non-invasive assessment tool in research settings, although newer modalities like peripheral arterial tonometry (PAT) and laser Doppler flowmetry are gaining traction in clinical applications. Importantly, endothelial dysfunction is not restricted to cardiovascular pathology alone; it is increasingly implicated in insulin resistance, autoimmune disorders like lupus, and even neurovascular diseases such as vascular dementia and Alzheimer’s, thus broadening its relevance across multiple medical domains.

Which Conditions Are Most Impacted by Endothelial Impairment and Why?

The most significant clinical associations of endothelial dysfunction are observed in cardiometabolic disorders. In type 2 diabetes mellitus, chronic hyperglycemia induces oxidative stress, impairs nitric oxide bioavailability, and accelerates endothelial senescence. This endothelial injury exacerbates microvascular complications like diabetic nephropathy and retinopathy, while also contributing to macrovascular issues such as coronary artery disease and peripheral arterial disease. In hypertension, increased mechanical stress on the vascular wall leads to endothelial activation and inflammation, promoting vascular remodeling and elevated arterial stiffness. These feedback loops make the endothelium both a target and mediator of disease progression, reinforcing its role as a critical diagnostic and therapeutic focal point.

Moreover, endothelial dysfunction has a prominent role in chronic kidney disease (CKD), particularly in accelerating the decline in renal perfusion and glomerular filtration rates. In patients with end-stage renal disease, systemic endothelial impairment correlates with elevated cardiovascular risk, the leading cause of mortality in this cohort. In autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, circulating inflammatory cytokines impair endothelial cell junctions and increase vascular permeability. This predisposition to vascular injury elevates cardiovascular risk, even in young patients. Pulmonary arterial hypertension (PAH) and erectile dysfunction also exhibit strong endothelial components, further underscoring the systemic implications of impaired vascular function. The convergence of these associations demonstrates the centrality of endothelial health in the management of multisystem diseases.

How Are Diagnostic and Therapeutic Strategies Evolving in This Space?

Technological advancements in endothelial function assessment are catalyzing a more proactive approach to disease detection and progression monitoring. Traditional methods like FMD, while accurate, require operator skill and specific environmental conditions, limiting scalability. In response, emerging devices using PAT, oscillometry, and bioimpedance are offering more accessible, automated alternatives for assessing microvascular reactivity. Wearable biosensors and digital health platforms are also being developed to continuously monitor vascular health parameters, offering potential for remote tracking of endothelial responsiveness in at-risk populations. Simultaneously, molecular diagnostics are refining the landscape with biomarker panels capable of detecting endothelial damage at the subclinical stage.

On the therapeutic front, several pharmacologic interventions are being repurposed or designed with endothelial protection as a core objective. Statins, ACE inhibitors, and angiotensin receptor blockers (ARBs) have shown endothelial-stabilizing effects independent of their lipid-lowering or antihypertensive properties. Newer classes of drugs, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, are demonstrating vascular protective effects in diabetic patients, partially attributed to improved endothelial function. Anti-inflammatory agents, nitric oxide donors, and antioxidants are also being explored in clinical trials, especially in diseases where oxidative stress is a prominent pathogenic driver. Furthermore, regenerative strategies involving endothelial progenitor cells (EPCs) and gene editing tools targeting endothelial nitric oxide synthase (eNOS) regulation are under early-phase development. These innovations are paving the way for targeted interventions aimed specifically at restoring endothelial equilibrium.

What Factors Are Fueling the Rising Demand in the Endothelial Dysfunction Market?

The growth in the global endothelial dysfunction market is driven by several factors that are converging across the clinical, technological, and regulatory ecosystems. Chief among these is the rising global burden of non-communicable diseases such as cardiovascular disease, diabetes, and kidney disease-all of which have endothelial impairment as a common pathophysiological thread. The increasing emphasis on early diagnosis and personalized medicine is pushing the medical community to focus more intensively on endothelial biomarkers and vascular imaging techniques as predictive tools. This demand is further amplified by growing awareness of subclinical vascular damage among both clinicians and patients, especially in high-risk but asymptomatic individuals.

Additionally, the market is benefiting from expanding R&D investments into endothelial-targeted therapies by both pharmaceutical giants and biotech startups. The trend of repositioning existing cardiovascular drugs for endothelial restoration and the parallel development of novel agents with dual cardiometabolic and endothelial effects is broadening the therapeutic pipeline. Health systems are also starting to incorporate endothelial assessments into routine risk stratification models, particularly in advanced cardiac centers and metabolic clinics. Digital health integration is playing a key role as well, with AI-driven vascular analytics and mobile diagnostics platforms facilitating point-of-care testing and longitudinal tracking.

Finally, regulatory bodies are increasingly supporting innovation in this space through accelerated pathways and orphan designations for therapies addressing rare endothelial-related conditions such as PAH and systemic sclerosis. Public health campaigns promoting cardiovascular risk management and lifestyle modification are creating an enabling environment for preventive strategies centered around endothelial wellness. With its expanding diagnostic relevance, therapeutic implications, and technological applicability, the endothelial dysfunction market is poised for substantial growth, influencing the broader landscape of chronic disease management.

SCOPE OF STUDY:

The report analyzes the Endothelial Dysfunction market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Invasive Tests, Noninvasive Tests); Cause (Hypertension, Diabetes, Obesity, Hypercholesterolemia, Bechets Disease); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Alam Medical SaRL
  • Alvimedica
  • Amgen Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Endothelix Inc.
  • Everist Health Inc.
  • Glucox Biotech AB
  • Johnson & Johnson
  • Lawrence Berkeley National Laboratory
  • Medizinische Messtechnik GmbH
  • Novartis AG
  • OrbusNeich Medical Group
  • Perimed AB
  • Pfizer Inc.
  • Sanofi S.A.
  • SMART Medical Ltd
  • SphingoTec GmbH
  • Stealth Peptides Inc.
  • ZOLL Medical Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Endothelial Dysfunction - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cardiovascular and Metabolic Syndromes Throws Spotlight on Endothelial Dysfunction
    • Growth in Atherosclerosis, Hypertension, and Diabetes Cases Drives Clinical Focus on Vascular Health
    • Emergence of Endothelial Biomarkers in Risk Stratification Strengthens Business Case for Diagnostic Development
    • Integration of Endothelial Function Testing in Preventive Cardiology Expands Diagnostic Market Opportunity
    • R&D in Nitric Oxide Pathway Modulation Spurs Innovation in Endothelium-Targeted Therapies
    • Increasing Use of Flow-Mediated Dilation (FMD) and Reactive Hyperemia Techniques Supports Functional Assessment
    • Surge in Demand for Point-of-Care Cardiovascular Risk Screening Accelerates Portable Device Adoption
    • Pharmaceutical Pipeline Development Targeting Endothelial Repair Fuels Innovation in Cardiometabolic Therapy
    • Adoption of AI-Based Image Analysis in Vascular Ultrasound Enhances Diagnostic Accuracy
    • Integration With Wearable Blood Pressure and Heart Rate Monitors Facilitates Longitudinal Monitoring
    • Public Health Campaigns on Lifestyle Risk Factors Strengthen Preventive Screening Measures
    • Clinical Guidelines Emphasizing Endothelial Health Encourage Early Detection and Intervention
    • Expansion of Research on Microvascular Endothelial Dysfunction Broadens Understanding of Disease Mechanisms
    • Collaborations With Academic Research Institutes Drive Device Validation and Regulatory Pathways
    • Growing Emphasis on Inflammatory Pathways and Immune Regulation Fuels Interdisciplinary Therapeutic Approaches
    • Increasing Role of Endothelial Function in Long COVID and Chronic Fatigue Syndromes Expands Research Funding
    • Emerging Evidence on Gender-Based Differences in Endothelial Dysfunction Promotes Personalized Risk Assessment
    • Use of Nutraceuticals and Antioxidants in Endothelial Health Drives Demand for Adjunctive Interventions
    • Regulatory Push for Cardiovascular Outcome Measures in Clinical Trials Elevates Focus on Vascular Function
    • Global Epidemiological Studies Highlight Regional Variability in Endothelial Dysfunction Prevalence and Risk Factors
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endothelial Dysfunction Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endothelial Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Endothelial Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Endothelial Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Invasive Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Invasive Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Invasive Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Noninvasive Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Noninvasive Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Noninvasive Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Bechets Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Bechets Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Bechets Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • JAPAN
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • CHINA
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • EUROPE
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Endothelial Dysfunction by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Endothelial Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • FRANCE
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • GERMANY
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Endothelial Dysfunction by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • INDIA
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Endothelial Dysfunction by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Endothelial Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Endothelial Dysfunction by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Endothelial Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030
  • AFRICA
    • Endothelial Dysfunction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Endothelial Dysfunction by Test Type - Invasive Tests and Noninvasive Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Endothelial Dysfunction by Test Type - Percentage Breakdown of Value Sales for Invasive Tests and Noninvasive Tests for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Endothelial Dysfunction by End-Use - Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Endothelial Dysfunction by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics End-Use, Hospitals End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Endothelial Dysfunction by Cause - Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Endothelial Dysfunction by Cause - Percentage Breakdown of Value Sales for Hypertension, Diabetes, Obesity, Hypercholesterolemia and Bechets Disease for the Years 2014, 2025 & 2030

IV. COMPETITION